Case Study: Determining Valued Clinical Trial Endpoints with Qualitative Payer Research

Issue:

Client has two oncology biologics in early stage development, with the potential of targeting multiple tumor types. The client wants to determine the best development approach.

Strategy: 

• Identified 20 payer medical and pharmacy directors with specific interest in biologics/oncology drug management.
• Conducted detailed interviews on hypothetical tumor types, clinical trial designs, and possible outcomes.
• Measured feedback on payer desired clinical and economic data.

Outcome:

• Determined risk of targeting tumor types that payers are developing clinical pathways on, with focus on generic drugs and biologics.
• Identified thresholds for perspectives of “clinical significance” with specific tumors (related to unmet need, patient population, etc.)